Empagliflozin in Heart Failure with a Preserved Ejection FractionStefan D. Anker, Milton Packer, Michele Senni et al.|New England Journal of Medicine|2021Cited by 4.6k
SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trialsFaı̈ez Zannad, Milton Packer, João Pedro Ferreira et al.|The Lancet|2020Cited by 1.4k
Effect of Empagliflozin on the Clinical Stability of Patients With Heart Failure and a Reduced Ejection FractionMilton Packer, Faı̈ez Zannad, Stefan D. Anker et al.|Circulation|2020Cited by 422
Effect of Empagliflozin on Cardiovascular and Renal Outcomes in Patients With Heart Failure by Baseline Diabetes StatusStefan D. Anker, Milton Packer, Javed Butler et al.|Circulation|2020Cited by 350
Empagliflozin and health-related quality of life outcomes in patients with heart failure with reduced ejection fraction: the EMPEROR-Reduced trialJaved Butler, Milton Packer, Stefan D. Anker et al.|European Heart Journal|2020Cited by 179